VIDEO: Data support further study of radiopharmaceuticals in metastatic prostate cancer

CHICAGO — In this video, Pedro C. Barata, MD, MSc, FACP, discusses preliminary safety, dosimetry and pharmacokinetic results from the first part of the phase 3 ProstACT Global study, presented at ASCO Annual Meeting.The study evaluated the investigational radio antibody-drug conjugate 177Lu rosopatamab tetraxetan (TLX591, Telix Pharmaceuticals), which targets prostate-specific membrane